A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancer

European Journal of Cancer

Volumn 50, Issue 1, 2014, Pages 40-49

  Lange, A ^a   Prenzler, A ^a   Frank, M ^a   Kirstein, M ^b   Vogel, A ^b   Von Der Schulenburg, J M ^a  

^a LEIBNIZ UNIVERSITY HANNOVER   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Advanced colorectal cancer; Bevacizumab; Cetuximab; Cost effectiveness analysis; Cost utility analysis; Health economics; Metastatic colorectal cancer; Monoclonal antibody; Panitumumab; Targeted therapy

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN; PANITUMUMAB; REGORAFENIB;

CANCER COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DATA BASE; DRUG COST; ECONOMIC EVALUATION; EMBASE; HUMAN; MEDLINE; METASTATIC COLORECTAL CANCER; ONCOGENE K RAS; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; SCISEARCH; SYSTEMATIC REVIEW;

ADVANCED COLORECTAL CANCER; BEVACIZUMAB; CETUXIMAB; COST-EFFECTIVENESS ANALYSIS; COST-UTILITY ANALYSIS; HEALTH ECONOMICS; METASTATIC COLORECTAL CANCER; MONOCLONAL ANTIBODY; PANITUMUMAB; TARGETED THERAPY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; HUMANS;

EID: 84891634642     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.08.008     Document Type: Review

References (29)

1. World Health Organisation. Globocan. 〈http://globocan.iarc.fr〉 2008 [accessed 06.03.13].
2. E. van Cutsem, B. Nordlinger, and A. Cervantes Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment Ann Oncol 21 Suppl. 5 2010 v93 v97
3. H.J. Lim, S. Gill, and C. Speers et al. Impact of irinotecan and oxaliplatin on overall survival in patients with metastatic colorectal cancer: a population-based study J Oncol Pract 5 2009 153 158
4. J. Tol, and C.J.A. Punt Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review Clin Ther 32 2010 437 453
5. U.S. Food and Drug Administration. Aflibercept, 〈http://www.fda.gov/ Drugs/InformationOnDrugs/ApprovedDrugs/ucm314438.htm〉 [accessed 06.03.13].
6. U.S. Food and Drug Administration. Regorafenib, 〈http://www.fda.gov/ Drugs/InformationOnDrugs/ApprovedDrugs/ucm321378.htm 〉 [accessed 06.03.13].
7. M.F. Drummond, M.J. Sculpher, G.W. Torrance, B.J. O'Brien, and G.L. Stoddart Methods for the economic evaluation of health care programmes 2005 Oxford University Press Oxford
8. German Institute of Medical Documentation and Information (DIMDI). 〈 http://www.dimdi.de〉.
9. Organisation for Economic Co-Operation and Development (OECD). StatExtracts: PPPs and exchange rates. 〈http://stats.oecd.org/Index.aspx? DatasetCode=SNA-TABLE4〉 [accessed 06.03.13].
10. J.J. Ofman, S.D. Sullivan, and P.J. Neumann et al. Examining the value and quality of health economic analyses: implications of utilizing the QHES J Manag Care Pharm 9 2003 53 61
11. B.M.R. Spiegel, L.E. Targownik, and F. Kanwal et al. The quality of published health economic analyses in digestive diseases: a systematic review and quantitative appraisal Gastroenterology 127 2004 403 411
12. E. Lee, C. Revil, and C.A. Ngoh et al. Clinical and cost effectiveness of bevacizumab + FOLFIRI combination versus FOLFIRI alone as first-line treatment of metastatic colorectal cancer in South Korea Clin Ther 34 2012 1408 1419
13. T. Shiroiwa, T. Fukuda, and K. Tsutani Out-of-pocket payment and cost-effectiveness of XELOX and XELOX plus bevacizumab therapy: from the perspective of metastatic colorectal cancer patients in Japan Int J Clin Oncol 15 2010 256 262
14. T. Shiroiwa, T. Fukuda, and K. Tsutani Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan Clin Ther 29 2007 2256 2267
15. P. Tappenden, R. Jones, S. Paisley, and C. Carroll The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales Eur J Cancer 43 2007 2487 2494
16. C. Asseburg, M. Frank, and C. Kohne et al. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting Clin Ther 33 2011 482 497
17. N. Starling, D. Tilden, J. White, and D. Cunningham Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment Br J Cancer 96 2007 206 212
18. T. Shiroiwa, Y. Motoo, and K. Tsutani Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer Mol Diagn Ther 14 2010 375 384
19. N. Mittmann, H. Au, and D. Tu et al. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial J Natl Cancer Inst 101 2009 1182 1192
20. P.R. Blank, H. Moch, T.D. Szucs, and M. Schwenkglenks KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective Clin Cancer Res 17 2011 6338 6346
21. A.S. Behl, K.A.B. Goddard, and T.J. Flottemesch et al. Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer J Natl Cancer Inst 104 2012 1785 1795
22. L. Annemans, E. van Cutsem, Y. Humblet, J.L. van Laethem, and H. Bleiberg Cost-effectiveness of cetuximab in combination with irinotecan compared with current care in metastatic colorectal cancer after failure on irinotecan-a Belgian analysis Acta Clin Belg 62 2007 419 425
23. J. Norum Cetuximab in the treatment of metastatic colorectal cancer: a model-based cost-effectiveness analysis J Chemother 18 2006 532 537
24. A. Vijayaraghavan, M.B. Efrusy, B. Goke, T. Kirchner, C.C. Santas, and R.M. Goldberg Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany Int J Cancer 131 2012 438 445
25. Medical Advisory Secretariat KRAS testing for anti-EGFR therapy in advanced colorectal cancer: an evidence-based and economic analysis Ont Health Technol Assess Ser 10 2010 1 49
26. Y. Wong, N.J. Meropol, W. Speier, D. Sargent, R.M. Goldberg, and J.R. Beck Cost implications of new treatments for advanced colorectal cancer Cancer 115 2009 2081 2091
27. D. Badger, J. Nursten, P. Williams, and M. Woodward Should All Literature Reviews be Systematic? Eval Res Educ 14 2000 220 230
28. S. Evers, M. Goossens, H. de Vet, M. van Tulder, and A. Ament Criteria list for assessment of methodological quality of economic evaluations: Consensus on Health Economic Criteria Int J Technol Assess Health Care 21 2005 240 245
29. T. Fojo, and C. Grady How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question J Natl Cancer Inst 101 2009 1044 1048